Date: 17 Oct 2006
Postmenopausal osteoporosis. What have we learned since the introduction of bisphosphonates?
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Over the past 12 years bisphosphonates have become a mainstay of treatment for postmenopausal osteoporosis. As a class, bisphosphonates significantly suppress bone turnover and increase BMD at the lumbar spine and other site through their direct inhibitory effects on osteoclasts. Alendronate and risedronate reduce the incidence of clinical vertebral and non-vertebral fractures. Etidronate and both oral and intravenous ibandronate reduce the incidence of clinical vertebral fractures, but data from primary analyses for reduction in non-vertebral fractures are currently less robust. Intravenous administration of zoledronate is under late-stage investigation for use in postmenopausal osteoporosis. Combinations of alendronate with estrogen or raloxifene provide a greater reduction in bone turnover markers and greater increases in BMD, but fracture risk reduction has not been determined. Overall, bisphosphonates are well tolerated. The most common side effects of oral bisphosphonates are upper gastrointestinal symptoms. Newer safety concerns about the use of bisphosphonates include osteonecrosis of the jaw and oversuppression of bone turnover. The optimal duration of bisphosphonate treatment has not been clearly established.
Stepan JJ, Alenfeld F, Boivin G, Feyen JH, Lakatos P. Mechanisms of action of antiresorptive therapies of postmenopausal osteoporosis. Endocr Regul 2003;37(4):225–38.PubMed
Pols HA, Felsenberg D, Hanley DA, et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int 1999;9(5):461–8.PubMedCrossRef
Schnitzer T, Bone HG, Crepaldi G, et al. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano) 2000;12(1):1–12.
Chesnut IC, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19(8):1241–9.CrossRef
Reginster JY, Adami S, Lakatos P, et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2-year results from the MOBILE study. Ann Rheum Dis 2006.
Emkey MZR, Lewiecki EM, Burdeska A, Mairon N, Rowell L, Eisman JA. Two-year efficacy and tolerability of intermittent intravenous ibandronate injections in postmenopausal osteoporosis: the DIVA study. 2005.
Sambrook P, Olszynski WP, Leigh C, Masanauskaite D, Bonvoisin B, Emkey R. Similar safety profile of intravenous ibandronate injection and daily oral ibandronate in postmenopausal osteoporosis: the DIVA study. Arthritis Rheum 2005;52(Suppl 9):S296.
Heaney RP, Saville PD. Etidronate disodium in postmenopausal osteoporosis. Clin Pharmacol Ther 1976;20(5):593–604.PubMed
Didronel: Label information. http://wwwfdagov/cder/foi/label/2006/017831s054lblpdf.
van Staa TP, Leufkens H, Abenhaim L, Cooper C. Postmarketing surveillance of the safety of cyclic etidronate. Pharmacotherapy 1998;18(5):1121–8.PubMed
Pamidronate: Label information. http://wwwfdagov/cder/foi/label/2005/020036s032lblpdf.
Abraham SC, Cruz-Correa M, Lee LA, Yardley JH, Wu TT. Alendronate-associated esophageal injury: pathologic and endoscopic features. Mod Path 1999;12(12):1152–7.
Graham DY, Malaty HM, Goodgame R. Primary amino-bisphosphonates: a new class of gastrotoxic drugs—comparison of alendronate and aspirin. Am J Gastroenterol 1997;92(8):1322–5.PubMed
Thomson AB, Marshall JK, Hunt RH, et al. 14 day endoscopy study comparing risedronate and alendronate in postmenopausal women stratified by Helicobacter pylori status. J Rheumatol 2002;29(9):1965–74.PubMed
Woo SB, Hellstein JW, Kalmar JR. Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006;144(10):753–61.PubMed
Brumsen C, Hamdy NA, Papapoulos SE. Long-term effects of bisphosphonates on the growing skeleton. Studies of young patients with severe osteoporosis. Medicine (Baltimore) 1997;76(4):266–83.CrossRef
Fournier P, Boissier S, Filleur S, et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 2002;62(22):6538–44.PubMed
Santini D, Vincenzi B, Avvisati G, et al. Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin Cancer Res 2002;8(5):1080–4.PubMed
Allen M, Iwata K, Phipps, R, Burr, DB. Risedronate and Alendronate similarly suppress remodelling and increase microdamage in beagles after 1 year of treatment at clinical doses. JBMR 2005.
Recker R. Alendronate effects on histomorphometric parameters: is there evidence for over-suppression of turnover? JMBR 2005
Emkey R, Zaidi M, Lewiecki EM, Burdeska A, Mairon N, Rowell L, et al. Two-year efficacy and tolerability of intermittent intravenous ibandronate injections in postmenopausal osteoporosis: the DIVA study. 2005.
Fosamax: Label information. (http://www.fda.gov/cder/foi/label/2005/020560s038_021575s007lbl.pdf).
Actonel: Label information. (http://www.fda.gov/cder/foi/label/2006/020835s019,%20021823s002lbl.pdf).
Boniva: Label information. (http://wwwfdagov/cder/foi/label/2006/021858s000lblpdf).
- Postmenopausal osteoporosis. What have we learned since the introduction of bisphosphonates?
Reviews in Endocrine and Metabolic Disorders
Volume 7, Issue 1-2 , pp 101-112
- Cover Date
- Print ISSN
- Online ISSN
- Kluwer Academic Publishers-Plenum Publishers
- Additional Links
- Postmenopausal osteoporosis
- Industry Sectors